MedTrace Logo

The Possible Effects of Roflumilast on Obesity Related Disorders

NCT04800172 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2022-04-05

No results posted yet for this study

Summary

Evaluation of the possible effects of roflumilast on weight, glucose and lipid metabolism, insulin resistance, oxidative stress and inflammatory process in prediabetic obese subjects.

Conditions

Interventions

DRUG

Roflumilast

administration of roflumilast 500 mcg tablet once daily for 3 months.

DRUG

placebo

administration of placebo tablet once daily for 3 months.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Sara M Zayed · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2022-03-31
Completion
2022-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04800172 on ClinicalTrials.gov